Regenxbio (RGNX) Reports Q3 Loss, Misses Revenue Estimates

Regenxbio (RGNX) delivered earnings and revenue surprises of -57.47% and -37.64%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Leave a comment

Your email address will not be published. Required fields are marked *